IDYA News and Press, IDEAYA Biosciences Inc. From 10/24/23

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $1...

2023-10-23 17:42:52 ET Gainers: Redfin  ( RDFN ) +15% . Agilysys ( AGYS ) +11% . Medpace Holdings ( MEDP ) +5% . HomeStreet ( HMST ) +5% . IDEAYA Biosciences ( IDYA ) +5% . Losers: CareDx ( CDNA ) -8% . A...

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline PR Newswire 60% confirmed ORR% by RECIST 1.1 in HLA-A2(+) in 1L MU...

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma PR Newswire Proffered paper oral presentation at ESMO 2023 scheduled for Monday, October...

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma PR Newswire Initiated Phase 2 expansion of darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma based on prelimin...

2023-10-09 06:44:00 ET More on GSK, IDEAYA, etc. GSK: Strong Positioning And Trading At Historical Discount Merck Vs. GSK: The Game-Changer Race In Pharma Excellence GSK plc (GSK) BofA Global Healthcare Conference (Transcript) FDA experts recommend changes to...

IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day...

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer PR Newswire Fast Track designation granted by U.S. FDA for evaluation of IDE161 in adult patien...

2023-09-26 09:43:37 ET More on IDEAYA Biosciences IDEAYA's Triple Threat: Melanoma, Money, And Momentum Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead IDEAYA wins key milestone in GSK deal as FDA clears cancer trial Seeking Alpha ...

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations PR Newswire Fast Track designation granted by U.S. FD...